Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

The Rise of DIY Healthcare

by Team Lumida
October 6, 2025
in Health and Longevity
Reading Time: 3 mins read
A A
0
The Rise of DIY Healthcare
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • Patients increasingly self‑diagnose and manage care using direct‑to‑consumer lab tests, wearables, at‑home medical devices, and AI chatbots amid provider shortages and long wait times.
  • Large diagnostic players (Quest, Labcorp), device/wearable makers, digital‑therapeutics firms, telehealth platforms and AI‑health software stand to gain if consumer adoption scales.
  • Major risks: test/device validity and false positives, data/privacy and liability concerns, uneven clinical follow‑up, and uncertain reimbursement and regulatory regimes (FDA/CMS/HIPAA).
  • Outcomes are mixed: some validated home treatments show comparable efficacy (e.g., home phototherapy), while many consumer tests/products lack clinical validation and can mislead users.

What happened

Consumers are ordering lab tests directly and using devices (home ECGs, sleep‑apnea screening, blood‑pressure alternatives, wearable patches) and AI chatbots (ChatGPT and bespoke provider tools) to get faster answers and continuous monitoring. Companies like Quest and Labcorp now offer hundreds of consumer tests, and device innovation (patch seismometers, smart mirrors) is moving from prototype to commercialization. Health systems and insurers are experimenting with partnerships and coverage in selective cases.

Why it matters

The shift toward DIY healthcare creates sizable revenue opportunities across direct‑to‑consumer diagnostics, subscription monitoring services, device hardware and SaaS care‑coordination platforms, while also changing cost dynamics—payers and employers may favor validated home care that reduces expensive in‑person visits and hospitalizations, benefiting value‑based providers and lowering unit costs. Winners could see higher ARPU and recurring revenue, but incumbents with clinical credibility will fiercely defend share and new entrants face steep regulatory and trust hurdles; inaccurate or non‑actionable consumer results could erode confidence, invite liability, and compress valuations for speculative players.

What’s next

Watch regulatory and reimbursement signals (FDA guidance on DTC tests/devices, CMS coverage decisions and evolving HIPAA interpretations), plus the arrival of peer‑reviewed clinical validation and real‑world evidence showing reduced ER visits or better outcomes; strong commercial traction will show up as user retention, physician follow‑ups, subscription ARR and payer partnerships. Equally important are developments on liability and standards—litigation, professional‑society guidance, and certification efforts will separate clinically reliable products from low‑quality offerings and determine the pace at which DIY healthcare scales.

Source

Previous Post

Terraformation’s Tree‑Subscription Service

Next Post

Gold, Bitcoin Surge on Global Debt Concerns

Recommended For You

The Rush Back to the Office Is Stalling

by Team Lumida
2 weeks ago
man and woman sitting on table

Key Takeaways Powered by lumidawealth.com Large employers are increasing in‑office mandates (e.g., Microsoft, NYT, Paramount, NBCU), but average office attendance has barely risen. Enforcement is uneven: managers often tolerate...

Read more

More Older Americans Are Aging Alone

by Team Lumida
1 month ago
man and woman sitting on bench facing sea

Key Takeaways Powered by lumidawealth.com Roughly 16 million Americans aged 65+ live alone (≈28% of that cohort), a share nearly triple the 1950 level. Community providers are overstretched: nonprofits...

Read more

New Law Delays Medicare Drug Price Relief, Preserves High Costs for Blockbuster Medicines

by Team Lumida
2 months ago
New Law Delays Medicare Drug Price Relief, Preserves High Costs for Blockbuster Medicines

Key Takeaways: Powered by lumidawealth.com Medicare Price Negotiations Curtailed: The One Big Beautiful Bill Act, signed by President Trump, introduces new provisions that delay or exclude some of the...

Read more

Travel Insurance Becomes Essential as Emergency Medical Claims Surge for Travelers Abroad

by Team Lumida
3 months ago
Travel Insurance Becomes Essential as Emergency Medical Claims Surge for Travelers Abroad

Key Takeaways: Powered by lumidawealth.com Rising Medical Claims: For the first time in a decade, emergency medical expenses topped all other travel insurance claims in volume and dollar amounts...

Read more

AI Robot Massages Enter the Spa Scene, Challenging Traditional Therapists

by Team Lumida
3 months ago
AI Robot Massages Enter the Spa Scene, Challenging Traditional Therapists

Key Takeaways: Powered by lumidawealth.com Emerging Technology: AI-powered robot massage machines, such as Aescape, are being introduced in hotels and spas, including the W Scottsdale, Four Seasons Resort Orlando,...

Read more

America’s Protein Obsession Fuels a Booming Market, But Experts Are Concerned

by Team Lumida
6 months ago
black magnifying glass on white and brown marble table

Key Takeaways: Powered by lumidawealth.com Americans are consuming protein in unprecedented ways, with food companies introducing protein-infused products like chips, candy, coffee, and even water. The trend is driven...

Read more

Is Covid Accelerating Cognitive Decline? Long-Covid Patients Face Alarming Risks

by Team Lumida
6 months ago
Pandemic Aftershocks: Why Illnesses Are Surging Worldwide

Key Takeaways: Powered by lumidawealth.com Millions of long-Covid patients continue to experience cognitive difficulties, with some being diagnosed with mild cognitive impairment (MCI), a condition that can precede dementia...

Read more

Emerging Drugs from Lilly, Amgen, and Novartis Target Untreatable Cholesterol Linked to Heart Disease

by Team Lumida
6 months ago
white and blue medication pill blister pack

Key Takeaways: Powered by lumidawealth.com Lipoprotein(a), a genetic cholesterol variant untreatable by statins, increases the risk of heart attacks and strokes by 2-3 times for 1-2 billion people worldwide....

Read more

Doctors and Patients Struggle With Trust Amid a Broken Healthcare System

by Team Lumida
7 months ago
person sitting while using laptop computer and green stethoscope near

Key Takeaways: Powered by lumidawealth.com Trust between doctors and patients is eroding, with both sides frustrated by systemic issues like rushed appointments, corporate quotas, and communication breakdowns. Doctors cite...

Read more

U.S. Drug Overdose Deaths Decline by 25%, Marking Progress in the Fentanyl Crisis

by Team Lumida
7 months ago
round white pills

Key Takeaways: Powered by lumidawealth.com Overdose deaths in the U.S. dropped by 25% in the 12 months ending October 2024, with 82,000 fatalities reported. The decline is largely driven...

Read more
Next Post
Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

Gold, Bitcoin Surge on Global Debt Concerns

Trump Fires BLS Chief After Weak Jobs Report, Eyes More Fed Influence

Trump Pushes for Israel–Hamas Deal Ahead of Monday Talks

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

person running on concrete road

Marathon Running Surges: Record Participation Driven by Gen Z and Tech Innovation

December 31, 2024
woman in dress holding sword figurine

IRS Shuts Down $50 Billion Tax Loophole

June 18, 2024
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan Sees Upside for Chinese Bank Stocks on Stabilizing Margins and Growing Fees

August 19, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018